Three months of abaloparatide treatment rapidly improves bone formation and density: implications for orthopedic preoperative bone health optimization.

VanDerwerker NB, Mosiman S, Krueger D, Binkley N, Anderson PA, Bernatz J

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA25 Jul 2026

PMID42498818DOI10.1007/s00198-026-08126-yPepBankPUB-42498818

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, abaloparatide increased femoral neck BMD by 1.55% at 3 months from baseline.
In plain wordsIn postmenopausal women with osteoporosis, abaloparatide increased femoral neck bone density by 1.55% at 3 months from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral neck BMD in women
Study
n = 250
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 µg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Mean BMD change
1.55%
Femoral neck, women, 3 months
SD
0.28%
BMD percent change
Source sentences
Summary
In women, mean BMD percent increases at the same sites were 1.55 (0.28), 1.78 (0.21), and 4.42 (0.34) respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
At 3 months, mean (SD) BMD percent increases in men were 1.79 (0.35), 1.26 (0.26), and 4.14 (0.43), at the femoral neck, total hip, and lumbar spine, respectively.
Summary · context
The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine.
Summary · context
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk.
Summary · context
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed.
Report a problemFND-4249881804
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, abaloparatide increased total hip BMD by 1.78% at 3 months from baseline.
In plain wordsIn postmenopausal women with osteoporosis, abaloparatide increased total hip bone density by 1.78% at 3 months from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal hip BMD in women
Study
n = 250
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 µg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Mean BMD change
1.78%
Total hip, women, 3 months
SD
0.21%
BMD percent change
Source sentences
Summary
In women, mean BMD percent increases at the same sites were 1.55 (0.28), 1.78 (0.21), and 4.42 (0.34) respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
At 3 months, mean (SD) BMD percent increases in men were 1.79 (0.35), 1.26 (0.26), and 4.14 (0.43), at the femoral neck, total hip, and lumbar spine, respectively.
Summary · context
The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine.
Summary · context
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk.
Summary · context
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed.
Report a problemFND-4249881805
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, abaloparatide increased lumbar spine BMD by 4.42% at 3 months from baseline.
In plain wordsIn postmenopausal women with osteoporosis, abaloparatide increased lower spine bone density by 4.42% at 3 months from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLumbar spine BMD in women
Study
n = 250
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 µg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Mean BMD change
4.42%
Lumbar spine, women, 3 months
SD
0.34%
BMD percent change
Source sentences
Summary
In women, mean BMD percent increases at the same sites were 1.55 (0.28), 1.78 (0.21), and 4.42 (0.34) respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
At 3 months, mean (SD) BMD percent increases in men were 1.79 (0.35), 1.26 (0.26), and 4.14 (0.43), at the femoral neck, total hip, and lumbar spine, respectively.
Summary · context
The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine.
Summary · context
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk.
Summary · context
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed.
Report a problemFND-4249881806
04HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, abaloparatide increased femoral neck BMD by 1.79% at 3 months from baseline.
In plain wordsIn men with osteoporosis, abaloparatide increased femoral neck bone density by 1.79% at 3 months from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral neck BMD in men
Study
n = 149
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 µg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Mean BMD change
1.79%
Femoral neck, men, 3 months
SD
0.35%
BMD percent change
Source sentences
Summary
At 3 months, mean (SD) BMD percent increases in men were 1.79 (0.35), 1.26 (0.26), and 4.14 (0.43), at the femoral neck, total hip, and lumbar spine, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine.
Summary · context
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk.
Summary · context
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed.
Report a problemFND-4249881801
05HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, abaloparatide increased total hip BMD by 1.26% at 3 months from baseline.
In plain wordsIn men with osteoporosis, abaloparatide increased total hip bone density by 1.26% at 3 months from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal hip BMD in men
Study
n = 149
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 µg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Mean BMD change
1.26%
Total hip, men, 3 months
SD
0.26%
BMD percent change
Source sentences
Summary
At 3 months, mean (SD) BMD percent increases in men were 1.79 (0.35), 1.26 (0.26), and 4.14 (0.43), at the femoral neck, total hip, and lumbar spine, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine.
Summary · context
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk.
Summary · context
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed.
Report a problemFND-4249881802
06HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, abaloparatide increased lumbar spine BMD by 4.14% at 3 months from baseline.
In plain wordsIn men with osteoporosis, abaloparatide increased lower spine bone density by 4.14% at 3 months from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLumbar spine BMD in men
Study
n = 149
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 µg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Mean BMD change
4.14%
Lumbar spine, men, 3 months
SD
0.43%
BMD percent change
Source sentences
Summary
At 3 months, mean (SD) BMD percent increases in men were 1.79 (0.35), 1.26 (0.26), and 4.14 (0.43), at the femoral neck, total hip, and lumbar spine, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine.
Summary · context
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk.
Summary · context
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed.
Report a problemFND-4249881803
07HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, serum P1NP increased over threefold at 1 month with abaloparatide versus baseline.
In plain wordsIn women with osteoporosis, a bone formation marker increased over threefold at 1 month with abaloparatide versus baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseSerum P1NP in women
Study
n = 250
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 µg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Serum P1NP fold change from baseline
> 3 fold
1 month, women
Source sentences
Summary
Compared with baseline, serum P1NP increased over threefold at 1 month in women and men.
2 context sentences(design, population, supporting numbers)
Summary · context
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk.
Summary · context
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed.
Report a problemFND-4249881807
08HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, serum P1NP increased over threefold at 1 month with abaloparatide versus baseline.
In plain wordsIn men with osteoporosis, a bone formation marker increased over threefold at 1 month with abaloparatide versus baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseSerum P1NP in men
Study
n = 149
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 µg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Serum P1NP fold change from baseline
> 3 fold
1 month, men
Source sentences
Summary
Compared with baseline, serum P1NP increased over threefold at 1 month in women and men.
2 context sentences(design, population, supporting numbers)
Summary · context
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk.
Summary · context
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed. BMD and BTM data from 149 men and 250 postmenopausal treated with ABL for 12 months were assessed.
Report a problemFND-4249881808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.